A WCRI report explores telemedicine utilization.

WCRI explores how drug payments varied across 28 states for key drug therapy groups.

AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.

Silvia Sacalis and Tate Rice take turns in WorkCompWire’s Leaders Speak Series.

Artri Ajo King contains undeclared diclofenac, creating safety concerns.

Ancillary medical product and service shortages and how to manage them.

A new report from the CDC found that 10% of overdose deaths in 2019-2020 involved gabapentin.

A total of 19 states now allow for recreational marijuana in adults aged 21 and older.

Risk and Insurance® magazine speaks to industry professionals, including Healthe’s Director of Product Management, Tate Rice.

Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.

Millions of workers are changing occupations, leading to ripple effects for comp.

Spending and utilization are returning to pre-pandemic levels, with biologics growing in prominence.

The public comment period is underway for this action, which could help with safer drug disposal.

Healthe’s VP of Clinical Services will join a discussion on post-COVID lessons for workers’ comp.

VX-548 delivered significant improvements in pain with few adverse events.

Women workers were more adversely impacted by the pandemic and the recession.

Quest Diagnostics reports increased positivity rates for marijuana in employee drug screenings.

Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.

Carriers share their thoughts on successful RTW programs.

A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.

Nearly 500 stakeholders share their thoughts on industry challenges and priorities.

Proposed changes are open to public comment until April 11th.

After a drop in activity due to the pandemic, five states are now considering legislation.

Healthe’s VP of Industry and State Affairs, Sandy Shtab, joined an educational webinar from IAIABC.

Buprenorphine is an opioid used to treat pain, as well as opioid-use disorder.

Legislation could potentially reclassify gig workers as employees entitled to workers’ comp.

Drug advancements surrounding the prevention and treatment of COVID-19.

Since the start of 2022, at least 10 states are considering some form of marijuana legislation.

Healthe’s Director of Product Management talks to Risk & Insurance on how to attract and retain talent in the workers’ comp industry.

This autoimmune drug was approved for various arthritic and autoimmune diseases.

The initial results from a collaborative survey between Healthe and Risk & Insurance.®

Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.

New five-day rules are recommended, with variation depending upon vaccination status.

The Bureau of Labor Statistics reports that 4.5 million employees quit their jobs in November 2021.

Healthe’s SVP of Product Strategy and Innovation, Kristine Kennedy, discusses this topic with Risk & Insurance magazine.

Molnupiravir, Paxlovid, and AZD7442 have shown promise in Phase 3 trials.

Those previously infected by the virus may face long-term health complications.

A new study found that VR sessions averaged a 40% reduction in pain and decreased opioid use.

Rulings from U.S. District Courts have impeded vaccine requirements among certain workers.

All adults may now receive a booster shot of any COVID-19 vaccine.

A new naloxone drug and a new opioid-NSAID combination.

Strategies for a safer, healthier workforce amid COVID-19 and beyond.

All COVID-19 vaccines now have emergency use authorization for a booster dose.

One-third of employees have witnessed cannabis use during work hours.

Pre-pandemic, 951 claims received telemedicine, jumping to 21,000 during the pandemic.

Visit Healthe at WCI booth #913! Plus, a recap of a SAWCA roundtable, featuring Sandy Shtab.

A new migraine medication, various generics, and more.

Long-term health impacts of COVID-19 can complicate claims

A WCRI study found that in some states 17% of workers receive topical analgesics.

Take our survey and share your thoughts on where the industry is headed.

Take part in our virtual speaking sessions at PRIMA and Comp Laude!

The Pfizer vaccine receives full FDA approval, while a new EUA authorizes booster shots for certain populations.

Healthe’s Director of Enterprise Analytics discusses in WorkCompWire how natural language processing can assist with claim review, population management, and more.

Less than 1% of gabapentin prescriptions were prescribed for an FDA-approved diagnosis.

All federal employees are impacted, as are companies with 100 or more employees.

Join our educational session on infectious disease safety in the workplace, and don’t miss a chance to take part in our industry survey!

The FDA approved first-time generics for Xeljanz, two COPD medications, and more.

Healthe’s Director of Product Management explains how centralized data helps claims professionals.

A new WCRI report explores the impact recent opioid legislation has had on injured worker care.

Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.